New drug doubles survival rates for pancreatic cancer patients
A groundbreaking development in pancreatic cancer treatment has moved oncologists to tears, with one researcher describing it as the most significant breakthrough of her 16-year career. Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer centre, shared emotional reflections on the progress, which offers new hope for a disease with a historically grim prognosis. The survival rate after five years remains at just 13%, often leaving doctors focused on palliative care rather than curative options.
New results from a global study involving 500 patients indicate that a daily pill called daraxonrasib may double survival rates for patients who have already undergone chemotherapy. The drug targets the RAS signaling pathway, a critical mechanism in cancer cell growth that was previously considered “undruggable.” Dr. Shroff emphasized the significance of this achievement, noting that the study compared the pill to chemotherapy and found it to be twice as effective.
The treatment has already made an impact on patients like former Nebraska Senator Ben Sasse, who shared his experience on “60 Minutes.” Diagnosed with metastatic pancreatic cancer, Sasse reported a 76% reduction in tumor volume and significantly reduced pain after starting the experimental drug. The FDA has granted expanded access to daraxonrasib for patients who have previously been treated for pancreatic cancer, though it remains under review for full approval.
While the drug carries some side effects, Dr. Shroff highlighted that the benefits appear to outweigh the risks. The overwhelming demand for daraxonrasib has prompted calls for accelerated distribution, with researchers urging swift action to bring the treatment to patients in need. If successful, the science behind this drug could inspire future advancements in treating other cancers.
Frequently Asked Questions
What is daraxonrasib?
Daraxonrasib is an experimental oral drug that targets the RAS signaling pathway, a key driver of cancer cell growth. It has shown promise in doubling survival rates for patients with advanced pancreatic cancer.
What is the current status of the drug?
The FDA has granted expanded access to daraxonrasib for patients who have previously been treated for pancreatic cancer. However, it remains an experimental drug awaiting full approval.
How does this treatment compare to chemotherapy?
Results from a 500-patient study indicate that daraxonrasib doubles survival rates compared to chemotherapy, with fewer severe side effects reported.
What role might this discovery play in future cancer research?